

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on 2-10-04

Cynthia L. Clay 54,930
Name of Attorney or Agent Registration No.
Cynthia L. Clay
Signature of Attorney or Agent

P&G Case 9081M

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of :
H. L. Focht et al. : Confirmation No. 2774
Serial No. 10/699,469 : Group Art Unit 1751
Filed October 31, 2003 : Examiner
For Striped Liquid Personal Cleansing Compositions Containing A Cleansing Phase and A
Separate Benefit Phase With Improved Stability

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, record is being made below in a Form PTO/SB08 of documents which the Patent Office may wish to consider in connection with examination of the above-identified patent application. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case. As provided in §1.97(g), no representation is made or intended that a thorough art search was made. As provided in 37 C.F.R. §1.97(h), this Information Disclosure Statement does not constitute an admission of any kind, and specifically is not an admission that the documents listed on attached form PTO/SB08 are, or are considered to be, material to the patentability of the above-identified patent application, as defined in 37 C.F.R. §1.56(b).

1. ☐ 37 C.F.R. §1.97 (b)(1) - U.S. Direct (within 3-months of filing a regular application or converted provisional)

This information disclosure statement, submitted under 37 C.F.R. §1.97 (b)(1), is being filed within three months of the filing date of a national application. Therefore, no fee is believed to be due.

BEST AVAILABLE COPY

2. ☒ 37 C.F.R. §1.97 (b)(3) - (>3 mo. after filing direct, but before 1st O.A.)

This information disclosure statement is being submitted under 37 C.F.R. §1.97 (b)(3). Applicants have not received an Office Action on the merits in the present application. Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter is enclosed to facilitate charging of the fee, if necessary.

3. ☐ 37 C.F.R. §1.97 (b)(4) - (before the mailing of a first Office Action after the filing of a request for continued examination under §1.114)

This information disclosure statement, submitted under 37 C.F.R. §1.97(b)(4), is being filed with the Request for Continued Examination (RCE) under 37 C.F.R. §1.114.

4. ☐ Information to be Considered with CPA Filing. This information disclosure statement is being filed with a Continued Prosecution Application (CPA) filed under 37 CFR 1.53(d).

5. ☐ 37 C.F.R. §1.97(c) with fee payment - (use after 1st Office Action & before Final Office Action or Notice of Allowance)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(c). Applicant(s) have not received a final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in the application (e.g., *Ex parte Quayle*) as of the date of this submission. Applicant(s) elect to pay the fee set forth in 37 C.F.R. §1.17(p). Please charge the fee set forth in 37 C.F.R. §1.17(p) to Deposit Account Number 16-2480 in the name of The Procter & Gamble Company. A duplicate copy of this letter (or a fee transmittal form) is enclosed to facilitate the charging of the fee.

ADDITIONAL ITEMS TO BE NOTED BY THE EXAMINER:

☐ (1) Copies of the cited references were previously cited by or submitted to the USPTO in prior application Case No. ____, U.S. Patent Application Serial No. __, filed __. Applicants claim priority to said application under 35 U.S.C. §120. Accordingly, copies of those documents are not provided with this Statement, pursuant to 37 C.F.R. §1.98(d).

OR

BEST AVAILABLE COPY

☒ (2) Copies of cited foreign patent and non-patent literature documents are enclosed.

OR

☐ (3) Copies of all said documents, except document No.'s _____, were submitted and considered in parent application U.S. Patent Application Serial No. _____, filed _____. Applicant(s) claim priority to said application under 35 U.S.C. §120. Accordingly, copies of document No.'s _____ are not provided with this Statement, pursuant to 37 C.F.R. §1.98(d). Copies of document No.'s _____ are enclosed. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case.

☐ (4) Pursuant to 37 C.F.R. §1.98(c), a concise explanation of the relevance of each cited reference that is not in the English language is provided.

☒ (5) Applicants also respectfully request the Examiner to consider and make of record the copending applications listed on the attached page.

☐ Additional information is attached.

Respectfully submitted,

By Cynthia L. Clay
Cynthia L. Clay
Attorney for Applicants
Registration No. 54,930
(513) 626-0575

February 10, 2004

Customer No. 27752

(IDS.doc)
(Last Revised 4/4/2003)


BEST AVAILABLE COPY

COPENDING APPLICATIONS

Entire copies of all co-pending applications (or the portion of the application and claims that caused it to be cited) must be sent with the IDS (see 37 CFR 1.98(a)(2)(iii))

<u>Atty. Docket No.</u>	<u>Serial Number</u>	<u>Inventor(s)</u>	<u>Filing Date</u>
8844	10/050,494	Wei et al.	01/16/2002
8863	10/358,803	Putnam et al.	02/05/2003
9042M	10/655,670	Focht et al.	09/18/2003

BEST AVAILABLE COPY



PTO/SB08A/B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031
Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

SHEET 1 of 1

COMPLETE IF KNOWN

Application Number	10/699,469
Confirmation Number	2774
Filing Date	10/31/2003
First Named Inventor	Heather Lynn Focht
Group Art Unit	1751
Examiner Name	
Attorney Docket Number	9081M

U. S. PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. ¹	DOCUMENT NUMBER Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	01	US-3,533,955 A	10/13/1970	Pader et al.	
	02	US-3,937,811 A	02/11/1976	Papantoniou et al.	
	03	US-4,159,028	06/26/1979	Barker et al.	
	04	US-5,059,414 A	10/22/1991	Dallal et al.	
	05	US-5,455,035 A	10/03/1995	Guerrero et al.	
	06	US-5,612,307 A	03/18/1997	Chambers et al.	
	07	US-5,929,019 A	07/27/1999	Puvvada et al.	
	08	US-5,947,335 A	09/07/1999	Milio et al.	
	09	US 5,965,500 A	10/12/1999	Puvvada	
	10	US-6,174,845 B1	01/16/2001	Rattinger et al.	
	11	US-6,176,391 A	01/23/2001	Rehkemper et al.	
	12	US-6,213,166	04/10/2001	Thibiant et al.	
	13	US-6,268,322 B1	07/31/2001	St. Lewis et al.	
	14	US-6,306,806 B1	10/23/2001	St. Lewis et al.	
	15	US-6,534,456	03/18/2003	Hayward et al.	
	16	US-6,534,457	03/18/2003	Shuman	
	17	US-2003/0180246	09/25/2003	Frantz et al.	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. ¹	FOREIGN PATENT DOCUMENT Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ⁶
	18	GB 1,277,324 A	06/14/1972	Chesebrough-Pond's		
	19	WO 94/10973 A1	05/26/1994	Unilever PLC		
	20	WO 98/27193 A1	06/25/1998	Procter & Gamble		
	21	WO 99/38489 A1	08/05/1999	Procter & Gamble		
	22	WO 99/38491 A1	08/05/1999	Procter & Gamble		
	23	WO 01/70926 A1	09/27/2001	Unilever PLC		
	24	WO 03/055456 A1	07/10/2003	Rhodia Inc.		

NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ⁶
EXAMINER			DATE CONSIDERED

BEST AVAILABLE COPY